The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.
It has been reported that mast cells secrete various bioactive substances (adipokines), in addition to serving as a place for energy storage. Adiponectin has been shown to be one of the adiopkines possessing anti-diabetic, anti-atherosclerotic and anti-inflammatory actions. It was recently shown that the blood adiponectin levels were reduced in cases of obesity. As a result, adiponectin has been attracting close attention as a factor playing a central role in the development of the metabolic syndrome. More recently, adiponectin receptors, Adiponectin Receptor 1 (AdipoR1) and Adiponectin Receptor 2 (AdipoR2) have been identified, inviting very close attention. AdipoR1 is expressed throughout the living body, but its expression is particularly prominent in the skeletal muscles. Unlike the G-protein- coupled receptors (GPCR) reported previously, AdipoR1 can be topologically characterized by an intracellular N-terminal and extracellular C-terminal. Structurally, this receptor seems to belong to a new family of receptors different from the GPCR. AdipoR1 serves as a receptor for globular adiponectin and full-length adiponectin. It has been shown that this receptor transmits signals for suppression of glycogenesis and stimulation of fat burning and sugar utilization through activation of AMP kinase, p36MAPK and PPARα. Measurement of AdipoR1 is expected to be useful in not only diabetes-related research, but also research on inflammation, atherosclerosis and, as has been shown more recently, tumors. For research use only, not for use in diagnostic procedures.
It has been reported that mast cells secrete various bioactive substances (adipokines), in addition to serving as a place for energy storage. Adiponectin has been shown to be one of the adiopkines possessing anti-diabetic, anti-atherosclerotic and anti-inflammatory actions. It was recently shown that the blood adiponectin levels were reduced in cases of obesity. As a result, adiponectin has been attracting close attention as a factor playing a central role in the development of the metabolic syndrome. More recently, adiponectin receptors, Adiponectin Receptor 1 (AdipoR1) and Adiponectin Receptor 2 (AdipoR2) have been identified, inviting very close attention. AdipoR1 is expressed throughout the living body, but its expression is particularly prominent in the skeletal muscles. Unlike the G-protein- coupled receptors (GPCR) reported previously, AdipoR1 can be topologically characterized by an intracellular N-terminal and extracellular C-terminal. Structurally, this receptor seems to belong to a new family of receptors different from the GPCR. AdipoR1 serves as a receptor for globular adiponectin and full-length adiponectin. It has been shown that this receptor transmits signals for suppression of glycogenesis and stimulation of fat burning and sugar utilization through activation of AMP kinase, p36MAPK and PPARα. Measurement of AdipoR1 is expected to be useful in not only diabetes-related research, but also research on inflammation, atherosclerosis and, as has been shown more recently, tumors. For research use only, not for use in diagnostic procedures.